Mucinous tumours of the rectum – Call for a change in neoadjuvant strategy

2021 ◽  
Author(s):  
Mufaddal Kazi ◽  
Jayesh Gori ◽  
Vivek Sukumar ◽  
Avanish Saklani
Keyword(s):  
Mucinous Tumours

scholarly journals Role of CA 19-9 in complex ovarian tumors

2016 ◽  
Author(s):  
Dhanya S. Thomas ◽  
Ajit Sebastian ◽  
Vinotha Thomas ◽  
Anitha Thomas ◽  
Rachel Chandy ◽  
...  
Keyword(s):  
Malignant Tumors ◽  
Ovarian Tumors ◽  
Benign Tumors ◽  
Ovarian Mass ◽  
Radiological Findings ◽  
Epithelial Tumors ◽  
Mucin Glycoprotein ◽  
Glycoprotein Antigen ◽  
Mucinous Tumours

Background: Cancer antigen 19-9 (CA 19-9) is a tumor-associated mucin glycoprotein antigen that may be elevated in healthy individuals as well as in patients with benign and malignant tumors. It is useful in the management of pancreatic and other gastrointestinal tumors. CA 19-9 is also elevated in benign and malignant ovarian tumors. Aim: To study the pattern of serum CA19-9 in complex ovarian tumors. Methods: The study design was descriptive, based on data collected from medical records. Patients with a complex ovarian mass, who were investigated with CA 19-9 and had undergone surgery, wereincluded in the study. The study duration was 2 years from January 2014 to December 2015. A total of 273 patients (119 - benign and 154 malignant) with complex ovarian mass and elevated CA 19-9 underwent surgery during the study period. Results: CA 19-9 was elevated in 55 patients (20%). Of these, 23 patients had benign tumors while 32 had malignant tumors.Among patients with benign tumors, 21 had dermoid, 23 had mucinous tumors and 75 had other types of tumors. CA 19-9 was elevated in 10 (47.6%) of the dermoids, 7 (30.4%) of the mucinous tumors and 6 (8%) of the other benign tumors. Among patients with malignant tumors, 138 were epithelial and 16 were non epithelial tumors. Of the epithelial tumors, 31 were mucinous and 107 were non mucinous types. Overall, 29 (21%) had elevated CA 19-9. Of the epithelial tumors, 22.6% of the mucinous type and 20.6% of the non mucinous type had elevated CA 19-9. Among the non-epithelial tumors, 3 (18.8%) had elevated CA19-9. Conclusion: CA 19-9 is elevated in several conditions but most likely to be raised in dermoid cysts and mucinous tumours. CA19-9 levels need to be interpreted along with clinical and radiological findings.

Progressive genomic alterations in intraductal papillary mucinous tumours of the pancreas and morphologically similar lesions of the pancreatic ducts

2003 ◽  
Vol 199 (4) ◽  
pp. 453-461 ◽  
Author(s):  
Davide Soldini ◽  
Matthias Gugger ◽  
Elisabeth Burckhardt ◽  
Andreas Kappeler ◽  
Jean A Laissue ◽  
...  
Keyword(s):  
Pancreatic Ducts ◽  
Genomic Alterations ◽  
Mucinous Tumours

Mac-2 binding protein and galectin-3 expression in mucinous tumours of the ovary: an annealing control primer system and immunohistochemical study

Pathology ◽  
2009 ◽  
Vol 41 (3) ◽  
pp. 229-233 ◽  
Author(s):  
Ju-Han Lee ◽  
Xianglan Zhang ◽  
Bong Kyung Shin ◽  
Eung Seok Lee ◽  
Insun Kim
Keyword(s):  
Immunohistochemical Study ◽  
Binding Protein ◽  
Galectin 3 ◽  
Mucinous Tumours

scholarly journals Germline whole exome sequencing of a family with appendiceal mucinous tumours presenting with pseudomyxoma peritonei

BMC Cancer ◽  
2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Mei Sim Lung ◽  
◽  
Catherine A. Mitchell ◽  
Maria A. Doyle ◽  
Andrew C. Lynch ◽  
...  
Keyword(s):  
Exome Sequencing ◽  
Whole Exome Sequencing ◽  
Pseudomyxoma Peritonei ◽  
Whole Exome ◽  
Mucinous Tumours

scholarly journals Pseudomyxoma peritonei (PMP) - a rare entity

2011 ◽  
Vol 15 (3) ◽  
pp. 79-81 ◽  
Author(s):  
Zaeem Ismail Ebrahim ◽  
Zarina Ismail Lockhat ◽  
Farzanah Ismail
Keyword(s):  
Pseudomyxoma Peritonei ◽  
Rare Complication ◽  
Morbidity And Mortality ◽  
Rare Entity ◽  
Loss Of Function ◽  
New Techniques ◽  
Visceral Organs ◽  
Mucinous Tumours

Pseudomyxoma peritonei (PMP) is a rare complication of mucinous tumours of appendiceal or ovarian origin that results in peritoneal and omental implants. Clinical morbidity and mortality arise from the fact that copious amounts of extracellular and peritoneal mucin result in distortion and loss of function of visceral organs. Therapeutic paracentesis is not possible because of the nature of the mucin. Currently, new techniques are being used to attempt to debulk the mucin volume; none, however, has lead to superior outcome.

Sign in / Sign up

Export Citation Format

Share Document